The Journal of Contemporary Dental Practice

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 21 , ISSUE 9 ( September, 2020 ) > List of Articles


GLUT-1 Expression: An Aid in Complementing the WHO Oral Epithelial Dysplasia Grading System

Priyanka Debta, Saswati Siddhartha, Fakir M Debta, Santosh K Swain, Mahesh C Sahu, Sangram Patro

Citation Information : Debta P, Siddhartha S, Debta FM, Swain SK, Sahu MC, Patro S. GLUT-1 Expression: An Aid in Complementing the WHO Oral Epithelial Dysplasia Grading System. J Contemp Dent Pract 2020; 21 (9):951-955.

DOI: 10.5005/jp-journals-10024-2870

License: CC BY-NC 4.0

Published Online: 19-01-2021

Copyright Statement:  Copyright © 2020; The Author(s).


Aim and objectives: The clinicopathologic parameters alone are not sufficient to precisely predict if oral potentially malignant disorders (OPMDs) remain unchanged, i.e., without any malignant changes, regress, or advance to oral squamous cell carcinomas (OSCC). Few of the OPMDs, with or without epithelial dysplasia, may transform to frank OSCC. Discovering various molecular markers that can predict OSCC transformation is essential to develop effective therapeutic strategies. GLUT-1 is one of the hypoxia as well as metabolic indicator markers that have been used to study the metabolic activity of the cells. Hence, given by the World Health Organization (WHO), GLUT-1 expression was studied in various grades of dysplasia to see whether it complements the WHO grading system (mild, moderate, and severe). Materials and methods: The study was carried out on paraffin-embedded tissues of 10 normal oral mucosa and 30 OPMD cases. OPMD cases were classified into hyperkeratosis, mild dysplasia, moderate dysplasia, and severe dysplasia groups. Immunohistochemistry was carried out to evaluate the expression of GLUT-1 antigen. Results: According to the WHO grading system of dysplasia, 11 (36.66%) cases were classified as hyperkeratosis, 9 (30%) cases were classified as mild dysplasia, 6 (20%) cases as moderate dysplasia, and 4 (13.33%) cases as severe dysplasia. There was a significant increase in GLUT-1 expression from normal to mild, moderate, and severe dysplasia (p value = 0.00). Conclusion: The expression of GLUT-1 marker complements the WHO grading system of oral epithelial dysplasia. Clinical significance: GLUT-1 expression can be used to complement the WHO grading system to grade epithelial dysplasia.

  1. Smith CJ, Pindborg JJ. Histological Grading of Oral Epithelial Atypia by the Use of Photographic Standards. Copenhagen: C. Hamburgers Bogtrykkeri; 1969.
  2. Barnes L, Eveson JW, Reichart P, et al. World Health Organization classification of tumors. Pathology and genetics of Head and neck tumors. International Agency for Research on Cancer (IARC). Head and Neck Tumors. Lyon: IARC Press; 2005. pp. 177–180.
  3. Pitiyage G, Tilakratne WM, Tavassoli M, et al. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 2009;38(10):737–752. DOI: 10.1111/j.1600-0714.2009.00804.x.
  4. Zhang X, Han S, Han HY, et al. Risk prediction for malignant conversion of oral epithelial dysplasia by hypoxia related protein expression. Pathology 2013;45(5):478–483. DOI: 10.1097/PAT.0b013e3283632624.
  5. Carvalho KC, Cunha IW, Rocha RM, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011;66(6):965–972. DOI: 10.1590/s1807-59322011000600008.
  6. Angadi VC, Angadi PV. GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma. J Oral Sci 2015;57(2):115–122. DOI: 10.2334/josnusd.57.115.
  7. Barnes L, Eveson JW, Reichart PA, et al. World health organization classification of tumours. pathology and genetics. Head and neck tumours. World Health Organization; 2005.
  8. Tilakaratne WM, Sherriff M, Morgan PR, et al. Grading oral epithelial dysplasia: analysis of individual features. J Oral Pathol Med 2011;40(7):533–540. DOI: 10.1111/j.1600-0714.2011.01033.x.
  9. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008;37(1):1–10. DOI: 10.1111/j.1600-0714.2007.00579.x.
  10. Van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 2009;45:(4-5):317–323. DOI: 10.1016/j.oraloncology.2008.05.016.
  11. Patil P, Nandimath K, Prabhu S, et al. Heat shock protein (HSP70) as a marker of epithelial dysplasia in oral dysplastic lesions: a clinicopathological study. J Oral Maxillofac Pathol 2015;10(1):53. DOI: 10.4103/0973-029X.157202.
  12. Juneja S, Chaitanya NB, Agarwal M. Immunohistochemical expression of BCl2 in oral epithelial dysplasia and oral squamous cell carcinoma. Indian J Cancer 2015;52(4):505–510. DOI: 10.4103/0019-509X.178411.
  13. Shailaja G, Kumar JV, Baghinath PV, et al. Estimation of malignant transformation rate in cases of oral epithelial dysplasia and lichen planus using immunohistochemical expression of Ki67, P53, BCl2 and Bax markers. Dent Res J (Isfahan) 2015;12(3):235–242.
  14. Nikitakis NG, Pentenero M, Georgaki M, et al. Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: current knowledge and future implications. Oral Oncol Oral Med Oral Pathol Oral Radiol 2018;125(6):650–669. DOI: 10.1016/j.oooo.2018.03.012.
  15. Gonzalez JC, Capida LA, Yanez SA, et al. p53 and p16 in oral epithelial dysplasia and oral squamous cell carcinoma: a study of 208 cases. Indian J Pathol Microbiol 2016;59(2):153–158. DOI: 10.4103/0377-4929.182037.
  16. Shetty SS, Krishnapalli R, Prabhu S. Assessment and comparison of p53 and p63 expression in oral epithelial dysplasia and squamous cell carcinoma. SRM journal of Research in Dental Sciences 2014;5(3): 149–154. DOI: 10.4103/0976-433X.138710.
  17. Sadiq S, Ahuja P, ingh N, et al. Immunohistochemical expression of p53 and Bcl2 in varying grades of oral epithelial dysplasia. Int J Pre Clin Dent Res 2015;2(4):17–25.
  18. Deepa AG, Nair BJ, VArun BR. Podoplanin expression in oral potentially malignant disorders and squamous cell carcinoma. J Clin Exp Dent 2017;9(12):1418–1428.
  19. Hanahan D, Wienberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–670. DOI: 10.1016/j.cell.2011.02.013.
  20. Bouquot JE, Speight PM, Farthing PM. Epithelial dysplasia of the oral mucosa-diagnostic problems and prognostic features. Current Diagnostic Pathology 2006;12(1):11–21. DOI: 10.1016/j.cdip.2005.10.008.
  21. Reisser C, Eichhorn K, Herold-Mende C, et al. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 1999;80(2):194–198. DOI: 10.1002/(sici)1097-0215(19990118);2-m.
  22. Burstein DE, Nagi C, Kohtz DS, et al. Immunohistochemical Detection of GLUT1, p63 and phosphorylated histone H1 in head and neck squamous intraepithelial neoplasia: evidence for aberrations in hypoxia-related, cell cycle- and stem-cell regulatory pathways. Histopathology 2006;48(6):708–716. DOI: 10.1111/j.1365-2559.2006.02407.x.
  23. Pereira KMA, Feitosa SG, Lima ATT, et al. Immunohistochemical evaluation of glucose transporter type 1 in epithelial dysplasia and oral squamous cell carcinoma. Asian Pac J Cancer Prev 2016;17(1): 147–151. DOI: 10.7314/apjcp.2016.17.1.147.
  24. Ganvir SM, Bamane SA, Katkade SP, et al. Depth of invasion and GLUT-1 as risk predictors in oral squamous cell carcinoma: an immunohistochemical study. Translational research of oral squamous cell carcinoma. Oral Oncol 2017;2:1–10.
  25. Warnakulasuriya S, Reibel J, Bouquot J, et al. Oral epithelialdysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008;37(3):127–133. DOI: 10.1111/j.1600-0714.2007.00584.x.
  26. Gadbail AR, Chaudhary MS, Sarode SC, et al. Ki67, CD105, α-SMA expressions better relate the oral epithelial dysplasia grading system of world health organization. J Oral Pathol Med 2017. 1–7. DOI: 10.1111/jop.12612.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.